What is GHK?
GHK is the Gly-His-Lys tripeptide. It is distinct from GHK-Cu, its copper complex. The selected study examined anxiety-like behavior in male rats.
Biological role or research focus
Peptide identity and preclinical behavior research.
An elevated plus-maze experiment does not establish anxiety treatment in people. Species, route, behavioral interpretation, and peptide identity all constrain translation.
Role reference: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Names you may encounter
Gly-His-Lys
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Glycyl-L-histidyl-L-lysine tripeptide
- Research focus
- Peptide identity and preclinical behavior research
- Featured evidence
- Rat behavioral study
- Source check
- October 4, 2026
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Quick answers
- Is GHK FDA approved?
- No. No FDA-approved drug contains GHK. Source ↗
- Is GHK safe?
- GHK without copper has been studied mainly in rat behavior and lab experiments. There are no published human safety studies. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is GHK banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| GHK behavior study in rats (2015) | Rat behavioral study | Male rats assessed in an elevated plus-maze experiment. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Rat behavioral study · 2015
GHK behavior study in rats
Did GHK alter anxiety-like behavior in rats?
- Population / model
- Male rats assessed in an elevated plus-maze experiment.
- Study design
- Preclinical comparison of GHK and sequence-related variants using behavioral measures.
- Main finding
- GHK increased time spent in open arms, interpreted as an anxiety-like behavioral change. Sequence modifications produced different responses; the reported response was not simply linear across exposure.
- Limits & context
- An elevated plus-maze experiment does not establish anxiety treatment in people. Species, route, behavioral interpretation, and peptide identity all constrain translation.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming GHK as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. ↗
International journal of molecular sciences · 2018 Jul 7 · Journal Article, Review
Read available full text ↗
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. ↗
The American journal of sports medicine · 2026 Jan · Journal Article, Review
The potential of GHK as an anti-aging peptide. ↗
Aging pathobiology and therapeutics · 2020 Mar 27 · Journal Article
Read available full text ↗
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. ↗
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1 · Journal Article, Review
Read available full text ↗
Risks & interactions
GHK without copper has been studied mainly in rat behavior and lab experiments. There are no published human safety studies.
No human safety studies were found for the copper-free tripeptide. Evidence on GHK-Cu skin products does not answer the safety of plain GHK used in other ways.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Anxiolytic effects of Gly-His-Lys in rats (2015) ↗ · The potential of GHK as an anti-aging peptide (review, 2020) ↗
What the featured evidence can tell us
This animal experiment does not establish human safety, an effective clinical exposure, or the safety of a copper-containing preparation.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Identity, route, and evidence limits
An elevated plus-maze experiment does not establish anxiety treatment in people. Species, route, behavioral interpretation, and peptide identity all constrain translation.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Plain GHK is also used as a cosmetic ingredient; S0 is aimed at pharmacological use. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
This page covers the free tripeptide and a preclinical behavioral experiment. Findings about copper-complex preparations, skin products, or injected formulations cannot automatically be transferred to GHK.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
How GHK works
The featured experiment studied behavior after GHK and related sequence variants. It did not establish a human brain mechanism or a clinical anti-anxiety treatment.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Molecular structure
Questions worth asking
- Can GHK-Cu research be counted as research on GHK alone?
- What population, comparator, and route were actually studied?
- An elevated plus-maze experiment does not establish anxiety treatment in people. Species, route, behavioral interpretation, and peptide identity all constrain translation.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Can GHK-Cu research be counted as research on GHK alone?
They are related but distinct materials. A copper complex changes chemical identity. Each study should specify which preparation was actually tested.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Anxiolytic effects of Gly-His-Lys peptide and its analogs. · 2015 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
